Patents by Inventor Pierre Guermonprez

Pierre Guermonprez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FOLR2+ MACROPHAGES AND ANTI-TUMOR IMMUNITY
    Publication number: 20240201192
    Abstract: The invention relates to tumor-associated FOLR2+ macrophages and gene signature thereof as a biomarker of favorable outcome and anti-tumor immunity useful for the prognosis and monitoring of cancer patients. The invention relates also to FOLR2+ macrophages as a therapeutic target for enhancing T cell immunity in the prevention and treatment of cancer and infectious diseases.
    Type: Application
    Filed: April 12, 2022
    Publication date: June 20, 2024
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite Paris Cite, Centre National de la Recherche Scientifique
    Inventors: Rodrigo Nalio Ramos, Pierre Guermonprez, Eliane Piaggio, Julie Helft
  • Vectors for molecule delivery to CD11b expressing cells
    Patent number: 10004794
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 26, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
    Publication number: 20160375119
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 29, 2016
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Vectors for molecule delivery to CD11b expressing cells
    Patent number: 9370564
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: June 21, 2016
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
    Publication number: 20120214206
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: June 27, 2011
    Publication date: August 23, 2012
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cécile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Vectors for molecule delivery to CD11b expressing cells
    Publication number: 20050238637
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions, and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: April 5, 2005
    Publication date: October 27, 2005
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Claude Leclerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Vectors for molecule delivery to CD11b expressing cells
    Publication number: 20040001867
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 1, 2004
    Inventors: Claude Leclerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi